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Abstract
Over the last two decades, rituximab (RTX) has played an important role in the treatment of some lymphoproliferative
malignancies and immune-mediated diseases. RTX administration is generally safe and well-tolerated, but side effects
including late-onset neutropenia, hypogammaglobulinemia, hepatitis B reactivation and rare cases of progressive multi-
focal leukoencephalopathy have been observed after its administration. Although there are no absolute contraindica-
tions regarding its use in people living with HIV (PLWH), the prescription of this drug has been principally limited in
patients with oncohematological diseases. In this report, we described the outcome of four PLWH who underwent RTX
therapy after the diagnosis of immune-mediated renal disease. The main RTX-associated adverse effects were leuko-
penia, late-onset neutropenia and decline of CD4þ and CD8þ T-cell counts. In addition, two of the four patients
experienced pneumonia requiring hospitalization within six months from the last RTX infusion. We suggest that RTX
should be used with caution in PLWH until further evidence emerges on its safety profile in this vulnerable population.
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Introduction
Rituximab (RTX) is a monoclonal chimeric antibody
used to target the antigen CD20 expressed on both
normal and neoplastic B-cells. Originally, it was includ-
ed in non-Hodgkin lymphoma and chronic lymphocyt-
ic leukemia therapies, whereas now it has also been
approved to treat several autoimmune diseases such
as rheumatoid arthritis, anti-neutrophil cytoplasmic
autoantibody (ANCA)-associated vasculitis and pem-
phigus vulgaris.1 In the last decade, off-label use of
RTX has been extended to immune-mediated renal dis-
eases including cryoglobulinemia-associated nephropa-
thy, membranous glomerulonephritis (MGN) and
lupus erythematosus. In addition, the promising results
of RTX in induction immunosuppressive therapy,
desensitization programs and treatment of antibody-
mediated rejection have broadened its therapeutic
application in the field of kidney transplantation.2,3
The mechanism of action of drug is only partially
understood. Besides the rapid depletion of pre-B and
mature B-cells expressing CD20 with subsequent
decrease of antibody production, RTX has an
immunomodulatory effect on both CD4þ and CD8þ
T-cells.4–6
Unfortunately, the beneficial effects of RTX-based
therapy are offset by a series of unwanted adverse
effects including late-onset neutropenia,7–9
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hypogammaglobulinemia10 and probably an early
decrease in CD4þ T-cell count.11–14 RTX seems also
associated with an increasing rate of infectious compli-
cations due to transient immunosuppression.15–20
Recently, Trivin et al.21 reported that in a retrospective
cohort of 98 patients treated with RTX for glomerul-
opathy, 25 of them (21.6%) experienced infectious
complications, most frequently bacterial in origin.
The tendency of RTX to increase the susceptibility
to infections has likely limited its use in people living
with HIV (PLWH). As a result, the drug has been prin-
cipally used as chemotherapeutic agent to treat lym-
phoproliferative diseases including non-Hodgkin
lymphoma22 and Castleman disease.23 The available
information about safety of RTX from these sources
is scarce and rather conflicting. Indeed, whereas a ran-
domized trial comparing R-CHOP (RTX plus cyclo-
phosphamide, doxorubicin, vincristine and
prednisone) with the CHOP regimen showed a higher
occurrence of fatal infections in patients treated with
RTX,24 a recent observational study found no differ-
ences in the rate of death for infections in patients who
received RTX for HIV-associated lymphoma.25 In light
of these opposing results and the little information
available on RTX in PLWH, we report our experience
in the use of RTX to target B-cells involved in the
pathogenesis of immune-mediated renal diseases,
focusing on its safety profile.
Cases presentation
Case 1
A 65-year-old Caucasian woman with a hisstory
of HIV-1 infection since 1996, hypertension,
Helicobacter pylori infection-associated gastritis, uter-
ine prolapse and depressive disorder developed
nephrotic syndrome in January 2017.
On presentation, laboratory tests were notable for
serum creatinine of 1.4mg/dl, albumin 2.2mg/dl and
spot urine protein/creatinine ratio of 8.3mg/mg. She
had a normal CD4þ T-cells count (1070 cells/ll) with
undetectable HIV-1 viral load (VL) (<40 copies).
Antiretroviral therapy (ART) consisted of three-drug
combination therapy with lamivudine, efavirenz and
abacavir.
The renal biopsy performed revealed a histological
pattern compatible with MGN (stage 2), confirmed by
serum levels of anti-phospholipase-A2-receptor auto-
antibodies (anti-PLA2R) of 237.64 UR/ml.
The patient was to receive intravenous (IV) infusion
of RTX 375mg/m2 once weekly for four consecutive
weeks in July 2017 without antimicrobial prophylaxis.
After three doses of RTX administered at a dosage
of 750mg, the patient experienced moderate
neutropenia (770 vs. 3250 cells/lL) in the absence of
fever or other signs of infections. A single dose of gran-
ulocyte colony-stimulating factor (G-CSF) was used to
raise the neutrophil count that reached a normal value
(3260 cells/lL) after 19 days from its nadir. After RTX
treatment, HIV VL remained unchanged, but T CD4þ
cell count decreased slightly to 611 cells/ll, even though
it remained in the reference range throughout the
observation period. Despite the decrease of anti-
PLA2R antibody levels (1.9UR/ml), proteinuria
remained steadily in the nephrotic range. In
December 2017, worsening renal function (creatinine
2.63mg/dl vs. a baseline creatinine of 1.5mg/dl)
prompted a course of second-line immunosuppressive
therapy consisting of steroids and cyclosporine. In
March 2018, she was admitted for fever and dyspnea
due to pneumonia that was treated with a course of
antibiotic therapy. At the end of one-year follow-up,
renal function remained stable (creatinine 1.76mg/dl,
eGFR 30ml/min) in the absence of proteinuria.
Case 2
A 24-year-old African woman living with HIV under-
went kidney transplantation in 2010 after four years
spent on dialysis for end-stage renal disease (ESRD)
secondary to HIV-associated nephropathy. Her medi-
cal history included also multinodular goitre. Her
immunosuppression consisted of everolimus in combi-
nation with reduced-dose cyclosporine whereas ART
was based on dolutegravir and rilpivirine. According
to our protocol, prophylaxis against cytomegalovirus
and Pneumocystis carinii infection was discontinued at
6 and 12months after transplantation, respectively.
In May 2017, her post-transplant course was com-
plicated by a slight increase in serum creatinine (1.5mg/
ml vs. a baseline creatinine of 1.3mg/ml) associated
with proteinuria greater than 400mg/dl.
Renal biopsy revealed a histological pattern compat-
ible with antibody-mediated transplant rejection. The
diagnosis was confirmed by the detection of a donor-
specific antibody (DSA) titer of 9068 mean fluorescent
intensity (MFI).
In light of these histological findings, a course of
immunosuppressive therapy including three boluses of
methylprednisolone and plasmapheresis was started.
Additionally, IV infusion of RTX 375mg/m2 once
weekly for four consecutive weeks was administered
in order to reduce antibody production, and mainte-
nance immunosuppressive therapy was potentiated
with the switch from cyclosporine and everolimus to
tacrolimus and mycophenolic acid. Prophylaxis with
trimethoprim-sulfamethoxazole was administered for
sixmonths.
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After 3.1months from the last RTX dose, a fall in
leukocyte and neutrophil counts was seen with a nadir
of 220 neutrophils/lL without infectious sequelae.
Four doses of G-CSF restored the neutrophil count
(2200 cells/lL) three days after its nadir. In April
2019, despite the disappearance of DSAs, a second
graft biopsy was performed for elevation in the serum
creatinine concentration (2.7mg/dl) associated with
significant proteinuria (1.5 g/daily). Histological evalu-
ation identified progression to the chronic stage of the
underlying humoral rejection.
Case 3
A 54-year-old African woman living with HIV-2 infec-
tion underwent kidney transplantation in 2012 after
12 years spent on dialysis for ESRD caused by malig-
nant hypertension. She also had a medical history of
type 2 diabetes mellitus and tertiary hyperparathyroid-
ism. Her immunosuppression consisted of everolimus
in combination with reduced-dose cyclosporine,
mycophenolic acid and steroids. ART was based on
lamivudine, maraviroc and raltegravir. HIV VL was
<40 copies and T-CD4þ cell count was 1080 cells/ll.
Post-transplant was complicated by two episodes of
biopsy-proven T-cell-mediated graft rejection that were
successfully treated with a short course of high-dose
corticosteroid.
In August 2013, a rapid increase in serum creatinine
level from baseline 1.8mg/ml to 2.78mg/dl prompted
renal graft biopsy.
The histological evaluation showed a pattern of
antibody-mediated rejection that was confirmed by a
high titer of DSA (>10,000 MFI both class I and II).
A course of combined immunosuppressive therapy
including three boluses of methylprednisolone, four
cycles of IV immunoglobulins and a single dose of
700mg of RTX was administered. The poor experience
of RTX in PLWH limited further infusions of the drug.
Prophylaxis against Pneumocystis jirovecii pneumonia
for six months started after the administration of anti-
rejection therapy. After five months from RTX treat-
ment, neutrophils reached a nadir of 230 cells/lL in the
absence of signs of systemic infection. Treatment with
G-CSF and mycophenolic acid withdrawal resulted in a
normalization of the WBC count one month later.
CD4þ T-cell count reached a nadir of 256 cells/ll a
few days after RTX treatment but returned to over
800 cells/ll one month after. Despite DSA becoming
negative and HIV VL remaining undetectable, a relent-
less worsening of renal function continued in the fol-
lowing months and the patient started hemodialysis in
May 2014.
Case 4
A 43-year-old Caucasian man living with HIV since
2013 underwent kidney transplantation in 2016 after
three years spent on peritoneal dialysis for ESRD
caused by MGN. His medical history also included
failure of a living-donor kidney transplant, HCV infec-
tion, hyperthyroidism, and previous syphilis, human
herpesvirus 6 and 7 infections. His immunosuppressive
therapy was a combination of tacrolimus, mycophe-
nolic acid and steroid, whereas ART was based on
dolutegravir and rilpivirine.
Two years after kidney transplant, the patient had a
decline in kidney function (serum creatinine raised
from a baseline of 1.7mg/dl to 2.6mg/dl) in the absence
of HIV replication (<40 copies).
A graft biopsy was performed. Detection of high
levels of DSA (>10,000 MFI for class II) and histologic
evidence of C4d staining and chronic tissue injury lead
to the diagnosis of chronic antibody-mediated
rejection.
A course of immunosuppressive therapy consisting
of a single dose of IV RTX (750mg) and IV immuno-
globulin (0.1 g/kg) was administered in October 2019.
After one week from the second infusion of RTX
(750mg), the patient developed severe Legionella pneu-
monia manifesting with acute dyspnoea and fever.
RTX therapy was discontinued and the infection was
effectively treated with levofloxacin without sequelae.
In March 2019, his CD4þ T-cell count dropped below
100 cells/mL and prophylaxis against Pneumocystis
carinii pneumonia was started. DSA showed a moder-
ate decline but renal function worsened quickly reach-
ing a pre-dialysis stage with a creatinine value of
5.17mg/dl in April 2019.
Discussion
This case-series showed that RTX should be used cau-
tiously in PLWH because it is associated with some
serious post-treatment side effects that may increase
the risk of infections. We described the outcome of
four PLWH who were treated with RTX after the diag-
nosis of renal disease triggered by immune-mediated
mechanisms. RTX was used as single agent for the
treatment of idiopathic MGN in a non-transplanted
subject and in combination with other immunosuppres-
sive agents for the treatment of antibody-mediated
graft rejection in three kidney transplant recipients
(Table 1). RTX was administered uniformly at dose
of 375mg/m2 once weekly with the total number of
infusions varying from one to four per patient. The
difference in RTX dose prescription was ascribed to
the early onset of significant adverse effects leading to
RTX withdrawal (case 1 and 4) and to the prudential
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use of RTX as a new antirejection drug in HIVþ KT
recipients (case 3). However, Despite the reduced
dosage compared to the standard protocol (once
weekly for four consecutive weeks), RTX consistently
decreased the level of serum anti-PLA2R antibodies
and DSA, serological markers of MGN and
antibody-mediated rejection, respectively.
In our patients, RTX was associated with clinically
relevant adverse effects such as leukopenia, neutrope-
nia, transient decline in CD4þ and CD8þ T-cell count
that potentially increased the susceptibility to infec-
tions (Table 1). After RTX therapy, we recognized a
decline in the neutrophil count which was clinically rel-
evant only in three patients (75%). Neutropenia devel-
oped after a period ranging from 0.7 to 4.8months
from the first RTX infusion in the absence of evident
signs of infection or sepsis. Neutropenia was responsive
to the administration of G-CSF in all three cases.
Two patients experienced bacterial pneumonia that
necessitated hospital admission. In both cases,
pneumonia was treated with intravenous antibiotics
and resolved without sequelae. We also noticed a ten-
dency toward the reduction of CD4þ and CD8þ T-cell
count within 6months from RTX therapy.
Unfortunately, we have few data to trace all changes
in immunoglobulin levels in these patients. However,
the decline of serum immunoglobulin levels was mod-
erate and probably multifactorial.
Late-onset neutropenia is a delayed adverse effect of
RTX. The incidence varies between 3 and 27%26 and it
seems to occur more frequently among patients treated
for hematological cancers27 than autoimmune dis-
eases.28 The mechanism by which RTX determines
neutropenia is still unclear. It has been suggested that
the aberrant reconstitution of B-cells after therapy ces-
sation may disrupt neutrophil homeostasis through
formation of anti-neutrophils antibodies or
production of chemokines. There is compelling
evidence supporting the theory of polymorphism in
the immunoglobulin (Ig)G Fc receptor (FccR).
Table 1. Main laboratory and clinical findings in people living with HIV who underwent rituximab therapy.
Case 1 Case 2 Case 3 Case 4
Age (years) 65 24 54 43
Immune-mediated kidney disease MGN AMR AMR AMR
Total number RTX infusions 3 4 1 2
RTX dose at each infusion (mg) 750 700 700 750
Leucocytes count (cells/lL)
Pre-RTX 8890 5280 7450 8590
Nadir post-RTX 3336 1720 2120 3390
Lymphocyte count (cells/lL)
Pre-RTX 2820 1600 1900 1470
Nadir post-RTX 2140 760 1004 220
Neutrophil count (cells/lL)
Pre-RTX 3250 2240 4420 4500
Nadir post-RTX 770 220 230 2800
Months from RTX to neutropenia* 0.7 3.1 4.8 4.7
Platelet count (103 cells/lL)
Pre-RTX 244 360 391 186
Nadir post-RTX 206 298 167 153
CD4þ T-cell count (cells/lL)
Pre-RTX 1070 758 1080 888
Nadir post-RTX 611 539 256 66
CD8þ T-cell count (cells/lL)
Pre-RTX 1321 573 891 554
Nadir post-RTX 1286 385 262 59
IgG/IgM/IgA (mg/dl)
Pre-RTX 526/142/117 1310/268/158 797/168/200 539/68/216
Nadir post-RTX 244/106/94 1113/208/179 587/65/167 483/20/142
G-CSF administration Yes Yes Yes No
Post-RTX infectious complications Pneumonia None None Pneumonia
Abnormal lab test results were considered secondary to the pharmacological effect of rituximab if they occurred within six months from the last
rituximab infusion and other potential causes (e.g., infections, drugs, plasmapheresis, etc.) were excluded.
AMR: antibody-mediated rejection; RTX: rituximab; G-CSF: granulocyte colony-stimulating factor; MGN: membranous glomerulonephritis; Ig:
immunoglobulin.
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Notably, subjects harboring the specific polymorphism
in the IgG Fc receptor FCGR3 position 158V/F have a
higher incidence of RTX-induced neutrophilia.21
Likely RTX interacts with high-affinity FCGR3 158
on neutrophils to induce a high apoptotic response in
these cells. Late-onset neutropenia remains an unpre-
dictable event and occurs after a median of 38–175 days
from last RTX dose.26 The severity of neutropenia is
variable, but in case of neutropenic fever, G-CSF may
be given to enhance the recovery of neutrophils.
In the literature, there are no data about the inci-
dence of RTX-induced neutropenia in PLWH. In this
group of patients, the drug has been mainly used for
HIV-associated lymphoproliferative disease23,29 and, to
a lesser extent, for rejections in solid organ trans-
plant,20,30–33 anti-glomerular basal membrane
disease34 and autoimmune thrombocytopenia.23 The
majority of information regarding safety and tolerabil-
ity of the drug has been gleaned from trials on patients
with hematologic malignancies where an alarmingly
high rate of fatal infections has been found.29,35 Only
a single episode of fatal progressive multifocal leukoen-
cephalopathy was reported following therapy with
RTX19 in one heart transplant recipient.
It is unclear if PLWH are more prone to developing
RTX-related side effects compared to other subsets of
the population. CD20 lymphopenia probably aggra-
vates CD4 lymphopenia, and consequently, can
worsen the state of immunodeficiency. However, in
absence of further randomized trials comparing RTX
with other chemotherapy or immunosuppressive regi-
mens, it is difficult to weigh the effects of RTX impli-
cated in late-onset neutropenia and infectious
complications because several confounding factors
may be involved in this cohort of patients. First, the
exposition to combination chemotherapy does not
allow us to differentiate the effect of each single
agent. Second, the use of protease inhibitors may
increase the risk of chemotherapy-induced neutrope-
nia.35 Lastly, low CD4 T-cell count (<450 cells/lL), a
condition commonly found in PLWH, is a risk factor
for infections and early death.36
The principal limitation of our study is the small
number of patients that does not allow us to generalize
our findings. Further studies should be carried out in a
much broader cohort of PLWH in order to clearly
weigh the risks and benefits of RTX therapy in this
population. When the use of RTX is inevitable, we
cautiously suggest avoiding the drug in neutropenic
patients with altered CD4 T-cell count. Given the risk
of delayed adverse effects, close follow-up is warranted
with frequent and careful monitoring of blood count,
CD4þ and CD8þ T-cell counts until further evidence
is found on the infectious risk associated with RTX
therapy.
Conclusions
In our series, RTX induced serious laboratory abnor-
malities that may have increased the susceptibility to
infections. Based on this observation, the use of this
drug deserves special attention in PLWH. Close
follow-up with careful monitoring of complete blood
count, CD4þ and CD8þ T-cells – even a long-time
after RTX therapy cessation – is needed in all PLWH
undergoing RTX therapy in order to identify and
potentially treat life-threatening infections.
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